Outcomes of infliximab dose escalation in patients with rheumatoid arthritis

MLA

George W. Reed, et al. “Outcomes of Infliximab Dose Escalation in Patients with Rheumatoid Arthritis.” Clinical Rheumatology, vol. 38, May 2019, pp. 2501–08. EBSCOhost, https://doi.org/10.1007/s10067-019-04543-z.

APA

George W. Reed, Lorie Ellis, S. Kafka, D. Parenti, Robert P. Magner, Stanley Cohen, Kimberly J. Dandreo, Ying Shan, Joel M. Kremer, & Raphael J. DeHoratius. (2019). Outcomes of infliximab dose escalation in patients with rheumatoid arthritis. Clinical Rheumatology, 38, 2501–2508. https://doi.org/10.1007/s10067-019-04543-z

Chicago

George W. Reed, Lorie Ellis, S. Kafka, D. Parenti, Robert P. Magner, Stanley Cohen, Kimberly J. Dandreo, Ying Shan, Joel M. Kremer, and Raphael J. DeHoratius. 2019. “Outcomes of Infliximab Dose Escalation in Patients with Rheumatoid Arthritis.” Clinical Rheumatology 38 (May): 2501–8. doi:10.1007/s10067-019-04543-z.